Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $1.73B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.71M in total
- 10
- 13F holdersQ2 2026, +17 vs. previous quarter
- 211
- 13F valueReported value at the end of Q2 2026
- $2.84B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $84.0M
- +54.0% year over year
- Net income, FY2025
- -$264.5M
- No comparable prior period
- Free cash flow, FY2025
- -$263.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $673.1M
- +8,426.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $264.5M (314.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 18.9M
- Shares sold short
- Change
- −1.67M
- −8.1% vs. previous
- Days to cover
- 7.17
- At average daily volume
Superinvestors holding NRIX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Nurix Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.3%
Nurix Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,793,196
- Value
- $43.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nurix Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)5:05 PM ET | Nov 4 | Same day | van Houte HansChief Financial Officer | SSale | −4.77K | $15.63 | −$74.6K | −10.0%42.7K after | 2 lots10b5-1 |
| Nov 4, 2026 (view filing)5:03 PM ET | Nov 2-3 | 2 days | Ring ChristineChief Legal Officer | SSale | −16.7K | $25.84 | −$431.9K | −79.1%4.41K after | 3 lots10b5-1 |
| Nov 2, 2026 (view filing)7:47 PM ET | Oct 30 | 3 days | van Houte HansChief Financial Officer | SSale | −2.83K | $26.28 | −$74.5K | −5.6%47.5K after | |
| Nov 2, 2026 (view filing)7:44 PM ET | Oct 30 | 3 days | Ring ChristineChief Legal Officer | SSale | −3.96K | $26.28 | −$104.0K | −20.5%15.3K after | |
| Nov 2, 2026 (view filing)7:42 PM ET | Oct 30-Nov 2 | 3 days | Hansen GwennChief Scientific Officer | SSale | −5.41K | $26.42 | −$142.9K | −4.2%123.5K after | 2 lots10b5-1 |
| Oct 15, 2026 (view filing)5:00 PM ET | Oct 15 | Same day | Hansen GwennChief Scientific Officer | SSale | −1.45K | $25.00 | −$36.3K | −1.2%117.2K after | 10b5-1 |
| Oct 14, 2026 (view filing)4:11 PM ET | Oct 14 | Same day | Gregory Julia PDirector | SSale | −22.6K | $23.40 | −$528.5K | −67.7%10.8K after | |
| Oct 2, 2026 (view filing)5:21 PM ET | Oct 2 | Same day | Ring ChristineChief Legal Officer | SSale | −5.79K | $23.19 | −$134.1K | −38.8%9.11K after | 10b5-1 |
| Sep 2, 2026 (view filing)7:42 PM ET | Sep 2 | Same day | Ring ChristineChief Legal Officer | SSale | −5.79K | $25.76 | −$149.1K | −38.8%9.11K after | 2 lots10b5-1 |
| Sep 1, 2026 (view filing)5:19 PM ET | Sep 1 | Same day | Hansen GwennChief Scientific Officer | SSale | −1.45K | $25.47 | −$37.0K | −1.2%117.2K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 211 holdersThe largest institutional positions in Nurix Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,770,349 | $212.8M | 0.00% | −155,293−1.7% | Reduced |
| Vestal Point Capital, LP | 8,050,000 | $195.3M | 4.56% | +1,550,000+23.8% | Added |
| Deep Track Capital, LP | 7,736,455 | $187.7M | 2.76% | +1,391,211+21.9% | Added |
| Rubric Capital Management LP | 7,227,778 | $175.3M | 1.61% | +4,753,893+192.2% | Added |
| FMR LLC | 5,485,215 | $133.1M | 0.01% | −56,056−1.0% | Reduced |
| Price T Rowe Associates Inc | 5,436,587 | $131.9M | 0.01% | +2,146,354+65.2% | Added |
| Morgan Stanley | 4,762,484 | $115.5M | 0.01% | −169,515−3.4% | Reduced |
| State Street Corp | 4,677,244 | $113.5M | 0.00% | −463,951−9.0% | Reduced |
| Baker Bros. Advisors LP | 4,658,556 | $113.0M | 0.57% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,495,529 | $109.1M | 0.00% | +68,417+1.5% | Added |
Holders of 5% or more of NRIX
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nurix Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.20%6.28M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Redmile Group, LLC | 13G/A | 8.10%8.78M shares | −1.80 ppfrom 9.90% | Feb 16, 20217 filings | Aug 14, 2026 | SEC |
| Vestal Point Capital, LP | 13G/A | 7.80%8.05M shares | +1.50 ppfrom 6.30% | May 15, 20262 filings | Aug 14, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 7.45%7.74M shares | +1.28 ppfrom 6.17% | Jun 10, 20229 filings | Aug 14, 2026 | SEC |
| Baker Bros. Advisors LP | 13G/A | 7.20%7.53M shares | – | Feb 14, 20225 filings | Feb 17, 2026 | SEC |